First-in-human results of an in-body tissue architecture-induced tissue-engineered vascular graft “Biotube” for application in distal bypass for chronic limb-threatening ischemia
Author:
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine,Surgery
Reference10 articles.
1. Global vascular guidelines on the management of chronic limb-threatening ischemia;Conte;J Vasc Surg,2019
2. A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia;Almasri;J Vasc Surg,2018
3. Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: an intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy;Bradbury;J Vasc Surg,2010
4. Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: analysis of amputation free and overall survival by treatment received;Bradbury;J Vasc Surg,2010
5. Development of long in vivo tissue-engineered “Biotube” vascular grafts;Nakayama;Biomaterials,2018
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Vascular Damage and Repair - Are Small-Diameter Vascular Grafts Still the “Holy Grail” of Tissue Engineering?;Physiological Research;2024-08-31
2. Bladder Reconstruction in Cats Using In-Body Tissue Architecture (iBTA)-Induced Biosheet;Bioengineering;2024-06-16
3. Development of Subcutaneous SSEA3- or SSEA4-Positive Cell Capture Device;Bioengineering;2024-06-08
4. Strategies to counteract adverse remodeling of vascular graft: A 3D view of current graft innovations;Frontiers in Bioengineering and Biotechnology;2023-01-10
5. Safety and efficacy of an iBTA-induced autologous Biotube® vascular graft and its preparation device BTM1 in below-the-knee bypass surgery for chronic limb threatening ischemia: A protocol for an open-label, single-arm, multicenter clinical trial;2022-12-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3